GlassScriptPhysician profile
Midhun Malla
NPI 1265865968
$143,927.18
in general payments reported to CMS, 2019-2025
22 companies · $117K in 2025
The $117K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $2,740 · 2021: $217 · 2022: $3,185 · 2023: $3,074 · 2024: $17K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Consulting Fee: $39K · Travel and Lodging: $17K · Food and Beverage: $4,819 · Honoraria: $3,650 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,173.55 |
| Consulting Fee | $39,371.00 |
| Travel and Lodging | $17,369.07 |
| Food and Beverage | $4,819.29 |
| Honoraria | $3,650.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $71,813.14 | 2019-2025 | Zynyz, Zynyz |
| Taiho Oncology, INC. | $13,979.18 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $12,936.52 | 2019-2025 | Onivyde, Somatuline Depot |
| Astrazeneca Pharmaceuticals LP | $11,563.55 | 2019-2025 | Lynparza, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $9,383.37 | 2025 | Opdivo |
| Astrazeneca Uk Limited | $8,990.99 | 2025 | |
| Exelixis INC. | $7,874.53 | 2023-2025 | Cabometyx |
| Daiichi Sankyo INC. | $3,185.25 | 2022 | |
| Astellas Pharma Global Development | $2,225.70 | 2024-2025 | Vyloy |
| Adc Therapeutics America, INC. | $500.00 | 2024 | |
| Pfizer INC. | $450.58 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $288.25 | 2023-2024 | |
| Seagen INC. | $212.25 | 2023 | Tukysa |
| Tempus Ai, INC | $130.90 | 2024 | |
| Boston Scientific Corporation | $116.89 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $99.99 | 2021 | |
| Amgen INC. | $74.99 | 2019 | |
| Lilly USA, LLC | $30.69 | 2019 | |
| Genentech USA, INC. | $29.99 | 2024 | Tecentriq |
| Novartis Pharmaceuticals Corporation | $26.16 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $14.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Midhun Malla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.